| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
22,108 |
14,251 |
$4.51M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,118 |
7,274 |
$2.90M |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,359 |
542 |
$405K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,571 |
1,158 |
$236K |
| 80053 |
Comprehensive metabolic panel |
4,542 |
4,201 |
$225K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,902 |
4,523 |
$200K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,789 |
810 |
$131K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
205 |
181 |
$100K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
368 |
338 |
$98K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
150 |
137 |
$21K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
157 |
149 |
$21K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
198 |
175 |
$19K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
184 |
174 |
$19K |
| 71045 |
Radiologic examination, chest; single view |
103 |
92 |
$13K |
| 81003 |
|
374 |
347 |
$13K |
| 36415 |
Collection of venous blood by venipuncture |
2,836 |
2,552 |
$11K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
68 |
68 |
$11K |
| 84443 |
Thyroid stimulating hormone (TSH) |
246 |
235 |
$8K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
1,597 |
1,347 |
$7K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
20 |
16 |
$6K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
15 |
15 |
$4K |
| 97597 |
|
35 |
13 |
$4K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
43 |
39 |
$4K |
| 80061 |
Lipid panel |
237 |
220 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
74 |
73 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
159 |
122 |
$3K |
| A6212 |
Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing |
561 |
255 |
$2K |
| 84484 |
|
35 |
28 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
87 |
77 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
12 |
12 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
67 |
38 |
$1K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
42 |
26 |
$1K |
| 83690 |
|
14 |
12 |
$1K |
| 83735 |
|
13 |
12 |
$969.12 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
63 |
58 |
$801.08 |
| 81001 |
|
15 |
13 |
$595.33 |
| A6213 |
Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing |
57 |
25 |
$422.74 |
| J2704 |
Injection, propofol, 10 mg |
12 |
12 |
$361.88 |
| 84439 |
|
26 |
26 |
$339.77 |
| A6207 |
Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
23 |
12 |
$215.23 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
14 |
12 |
$55.67 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
40 |
16 |
$0.00 |